Sno, Aftermarket Friday Drinking? Better cut down on that 20/20
Why rant again and again and again. We have all heard your rants before. Are they productive for you or anyone else? Foolish Sno.
Who cares if the koreans came to RGRX or vise versa? The deal for a near BK compnay was and is a great one. And the EU market is 100%!! What do you think asset will be worth when trials succeed? And if you feel trials will fail, you shouldnt be here. And JJ IS NOT running trial; the best in the business is. The EU will propel rgrx market cap to multiple 100's of millions. It will take a little time, but current news vacuum gives all a chance to take advantage of a low share price resulting from what you would claim is JJ's incompetence.
So, whine like a little girl about the past, or take advantage of the current situation...................
Come on sno, stop looking in the rear view mirror.
EU will be a very big market going forward. I posted the other day an analysts comment that it is the number 2 market in the world, ahead of China even. JV with Korea is nice, but the 100% of the EU market will mean more to the value here. And, you can buy rgrx now with little to no value being given. RGRX is a very unknown stock, take advantage of it, or not...........................
DES drug sales in the US accounted for a 63% share of the global market in 2012, and the US is anticipated to remain the most lucrative DES market in the near future. However, the key patent expiration of Restasis in the US and its concomitant approval in the EU will be key drivers in the US DES sales dropping to a 47% global market share in 2022, while the EU’s market shares will grow from 19% in 2012 to 41% in 2022.
As usual, its impossible to get an answer from you. I am not just talking about large offers above the inside offer. There have been many large offers on the inside lately which are very real. And, the offers above are most likely not spoofers. There is nothing but overhead supply. But, your refuse to answer the simple question.
The cabal of 3; ma, leiberman, and castle should find a new lackey to obfuscate here. Reseller is doing a very poor job. You know nothing of market dynamics.
The endless size offers, regardless of your factless opinions, are unusual and are not something investers who have been here for over a decade, are used to seeing. And the fact that they are appearing when stock price is on its LOWS, is not a comforting sign. So, Please give us your best guess as to where they are coming from. You do understand that these offers are sellers. Who is selling ??
And i speculate that management might be breaking the law because they have, over recent years, lied to shareholders and taken huge relative salaries and stock bonuses while shareholders have gotten nothing but losses. This does not instill any confidence in their integrity. For this, they have no one but themselves to blame. Can you undestand reseller???
Sure are paying this guy alot. Hope he is worth it. Interesting on that 12m dollar figure for future raise. They would need a much higher stock price to be able to do that.
On October 5, 2015, the Company entered into a three-year employment agreement with Dr. Tulip to join the Company as President. The employment agreement provides for a base salary of $320,000, which amount shall increase to $375,000 per year upon the completion of a bona fide firm commitment underwritten public offering of the Company in which it raises gross proceeds of at least $12,000,000. Dr. Tulip is entitled to an annual bonus in such amount and based upon such criteria as the Company's Board of Directors or Compensation Committee shall determine. For the calendar year ending December 31, 2016, the maximum bonus payable to Dr. Tulip will be $125,000, which bonus will be primarily based upon successfully achieving the financial business and clinical milestones as set forth in the agreement. In addition, Dr. Tulip is eligible for grants of awards under the Company's 2011 Equity Incentive Plan as the Company's Board of Directors or Compensation Committee may from time to time determine. Dr. Tulip shall initially be granted 500,000 stock options pursuant to the terms of the Company's 2011 Equity Incentive Plan, which options shall vest equally over three years upon each anniversary of his employment with the Company
Shorts surprised by quick move on rs. If you dont think there are many shorts here, check out regsho.finra.
Stock did 13 million shares the last pre split day, with OVER 5 million shorted. Shorts in big trouble here. Great move by CEO
Great comments, trot. There is just no way big pharma was going to give little rgrx the type of deal the Koreans agreed to. But, initially, the Koreans were an unknown so rgrx was risking if they were credible; they had little money to do any of it at the time. But, through the last couple months, we now know they are a very serious, credible partner and have done everything they have said, even ahead of schedule; and they have the funds.
The one thing you didnt mention, which i beleive to be the real unappreciated asset, is the 100% ownership of the EU market. Its amazing to me the they are in essence funding a trial to be used for this market, and receiving no ownership. It is not in rgrx's share price at all right now, but if trial successful, it will prove to be that binary asset...............IMHO.
I think the long time retail investors who were here for decades for EECP have done their selling. But, as you say, where is that endless supply coming from. IMHO....given that total lack of integrity that Castle, Ma and Leiberman have shown over the years, i would not be surpised if one or more of them was selling and not reporting same. Or, it may well be the estate of the old man who recently died. The small purchase his recently hired relative made is just a token smokescreen. There can be no other source of such endless stock.
Real bottom line here is that none of these BUMS can be trusted. Ma has lied many times over the years on CCs. And leiberman and castle have really milked this cash cow dry at all shareholders expense...........what a shame.
IT will take a couple days for avxl to be transferred to avxld shares. So, difficult to sell if you wanted to.
Shorts are caught flatfooted here. No warning on rs and now avxld too illiquid to cover and cant trade avxl. Could spike much higher.
Hey arden, lots to talk about in rgrx. Biggest Q coming up in the company's history. Take your off topic silly stock recommendations to the appropriate boards. Why do you feel a need to post such nonsense? How is it germane to rgrx? Rhetorical. no need to..
Sno, you cant even keep the proper track with what is happening here at little rgrx, and yet you presume to know my positions? Other than a winning hand in ZIOP and SCLN, have i ever said anything about my positions.
I dont know what you smoke during the day, put you need some serious help.
JJ is nobody's fool, like little snojob. He gets the Koreans to pay for trial, and gets some JV and some royalty in US market; very good. But, gets 100% of the EU market in dry eye. That is a huge market, bigger than china, and its all rgrx. That is a great deal for realistic holders here, if you consider that rgrx was bargaining with a very weak hand. Say what you want, but the EU will the the catalyst and once trials are successful, big pharma will want that asset.
How many little bio's can get another entity to fully fund a P3 trial and then have that entity NOT participate, in any way, in the profits in the 2nd largest market in the world. I am sorry you cant see it sno, through all that smoke but you might want to add to that buy you made at 50 cents..........
Would he join a sinking ship....dont think so................new era.........
Fpmi announced today that Dr. Thomas H. Tulip will join the company as President and will be responsible for the Company's day-to-day operations, with a focus on global product and business development strategies
Sno's most recent statement on rgrx's TB4 ownership rights. Does anyone see EU mentioned?
"About 65-70% of Restasis sales are US..and it is the US that RGRX did the venture on. So that hutrts a bit. teh good news is that RGRX ill owns rights of TB 4 eyes in Canada.I think Mexico...South America..Africa and I think India..but those markets are smaller.".
Then his last post:
"And yes, RGRX still owns valuabel Europe right. I STATED THAT"
Sno, you make such a fool of yourself everytime you post. The lies, misinformation and bashing continue. Its all in the failed scln playbook
EU is the big money maker for rgrx. They have 100% rights for TB4 there and will use the Korean trials(all payed for by Koreans) to apply to the European Commission. Once big pharma sees a good trial result next year, rgrx will be sold for exclusive rights to europe, even if another trial is needed. Thats the play and is only a couple months away. This was the endgame for insiders all along. Get the trial payed for and keep the EU. RGRX will be sold by next year to European Pharma as asset appreciates and derisks.
The ophthalmic drugs market can be segmented on the basis of geography and treatment drugs. Geographically, the ophthalmic drugs market is divided into North America, Europe, Asia-Pacific, and Rest of the World. North America leads the global ophthalmic drugs market, followed by Europe, owing to the increasing support from the government, technological advances, and presence of major industry participants. Asia-Pacific is one of the key markets for ophthalmic drugs due to growing patient pool, increase in healthcare expenditure, and infrastructure in emerging economies such as China and India, and rising disposable income.
"And if G Tree decides to sell TB 4 rightsin USA.they get 75% of those proceeds..RGRX 25%.. at that point, RGRX will be brought down tp a royalty interst of high single digits. That is it. G Tree will probably get higher.
About 65-70% of Restasis sales are US..and it is the US that RGRX did the venture on. So that hutrts a bit. teh good news is that RGRX ill owns rights of TB 4 eyes in Canada.I think Mexico...South America..Africa and I think India..but those markets are smaller.."
You do not know if high single digits or low double digits. No one knows if Gtree will sell? Gtree will get higher? You dont know any of that. And the biggest market that rgrx has you convenently choose to not mention......the EU.
And no one ever mentioned 49% of JV. The koreans are paying for the whole trial.
Wow, you are really right back to that failed scln playbook.
You followed for years and bashed while others, like B7 and myself, bought hand over first well below a buck. But, just like here, you trash company with misinformation. So, your history can not be avoided. And this makes your comments worthless.
First, everyone knows rgrx doesnt own 100% of the dry eye indication. The fact that i didnt repeat the obvious is not a lie...........foolish sno
And second, you dont address your "mistakes". Did you not say in plan fact before the start of trials that the koreans would not have the money and would wait for the china studies? Are you know going to take down those post too?
And third, how about your insistence that rgrx would get in the bio index? Are you going to rewrite history there too.
Sno, you are a very small player here, and your factual history of lies and mistakes makes you a follish waster of everyones time.